# Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2015

- Company: [Amphastar Pharmaceuticals, Inc.](/companies/amph.md) (CIK 1297184)
- Form: 10-Q
- Filed: 2015-08-13
- Accepted by EDGAR: Aug 13, 2015, 16:00 ET
- Period: 2015-06-30
- Accession: 0001171843-15-004674
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1297184/000117184315004674/gff10q_081315.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1297184/000117184315004674/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-04-01 to 2015-06-30 | $53.9m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2015-01-01 to 2015-06-30 | $110.7m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-04-01 to 2015-06-30 | $40.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2015-01-01 to 2015-06-30 | $84.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2015-04-01 to 2015-06-30 | $13.3m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2015-01-01 to 2015-06-30 | $26.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2015-04-01 to 2015-06-30 | $10.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2015-01-01 to 2015-06-30 | $17.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2015-04-01 to 2015-06-30 | −$10.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-01-01 to 2015-06-30 | −$17.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-04-01 to 2015-06-30 | $210.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2015-01-01 to 2015-06-30 | $551.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-04-01 to 2015-06-30 | −$3.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2015-01-01 to 2015-06-30 | −$9.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-04-01 to 2015-06-30 | −$6.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2015-01-01 to 2015-06-30 | −$7.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-04-01 to 2015-06-30 | −$0.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2015-01-01 to 2015-06-30 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-04-01 to 2015-06-30 | −$0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2015-01-01 to 2015-06-30 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-04-01 to 2015-06-30 | 44,849,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2015-01-01 to 2015-06-30 | 44,725,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2015-01-01 to 2015-06-30 | $3.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2015-01-01 to 2015-06-30 | $6.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2015-01-01 to 2015-06-30 | $741.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2015-06-30 | $74.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-06-30 | $203.9m | us-gaap:AssetsCurrent |
| Total assets | at 2015-06-30 | $398.9m | us-gaap:Assets |
| Current liabilities | at 2015-06-30 | $69.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-06-30 | $113.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-06-30 | $285.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 30,626 characters.

*The following discussion of our financial condition and the results of operations should be read in conjunction with the “Condensed Consolidated Financial Statements” and notes thereto included elsewhere in this Quarterly Report on Form 10-Q, or Quarterly Report. This discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the “Special Note About Forward-Looking Statements,” above.*

### Overview of Amphastar

Amphastar Pharmaceuticals, Inc., together with our wholly-owned subsidiaries, International Medication Systems, Limited, or IMS; Amphastar Laboratories, Inc.; Armstrong Pharmaceuticals, Inc., or Armstrong; Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; and Amphastar France Pharmaceuticals, S.A.S., or AFP, is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically-challenging generic and proprietary injectable and inhalation products. In 2014, we commenced sales of insulin API products. We currently manufacture and sell 18 products including Amphadase®, which we plan to re-launch in the fourth quarter of 2015. Additionally, we are developing a portfolio of 15 generic and six proprietary injectable and inhalation product candidates.

Our largest product by net revenues is currently enoxaparin sodium injection, the generic equivalent of Sanofi S.A.’s Lovenox®. Enoxaparin is a difficult to manufacture injectable form of low molecular weight heparin that is used as an anticoagulant and is indicated for multiple indications, including the prevention and treatment of deep vein thrombosis.

We have agreements with established group purchasing organizations and wholesaler networks to distribute enoxaparin, which is marketed under our own label for the hospital and clinic market. For the U.S. retail market, we have an agreement with Allergan plc, or Allergan, to distribute enoxaparin, which is marketed under their subsidiary Actavis’ label.

In June 2015, we received approval of our new drug application, or NDA supplement for Amphadase®. This marks the first approved starting material from ANP and signifies that our facility located in Nanjing, China has been qualified by the U.S. Food and Drug Administration, or FDA. Amphadase® will compete in the hyaluronidase market and is used to improve the resorption of radiopaque agents. We plan to re-launch Amphadase® in the fourth quarter of 2015.

Our pipeline of 22 generic and proprietary product candidates is in various stages of development and targets a variety of indications. With respect to these product candidates, we have filed three abbreviated new drug applications and one NDA with the FDA.

To complement our internal growth and expertise, we have made several strategic acquisitions of companies, products and technologies. These acquisitions collectively have strengthened our core injectable and inhalation product technology infrastructure by providing additional manufacturing, marketing and research and development capabilities including the ability to manufacture raw materials, APIs and other components for our products.

### Business Segments

Our performance will be assessed and resources will be allocated based on the following two reportable segments: (1) finished pharmaceutical products and (2) active pharmaceutical ingredients, or API products. The finished pharmaceutical products segment currently manufactures, markets and distributes enoxaparin, Cortrosyn®, naloxone, lidocaine jelly, as well as, various other critical and non-critical care drugs. The API segment currently manufactures and distributes recombinant human insulin and porcine insulin. Information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. Factors used to identify our segments include markets, customers and products.

For more information regarding our segments, see "Part I – Item 1. Financial Statements – Notes to Consolidated Financial Statements – Segment Reporting."

### Results of Operations

### Three Months Ended June 30, 2015 Compared to Three Months Ended June 30, 2014

### Net revenues

*(in thousands)*

| Net revenues Finished pharmaceutical products | Three Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Enoxaparin | $19,541 | $27,225 | $(7,684) | (28%) |
| Other products | 30,534 | 21,676 | 8,858 | 41% |
| Total finished pharmaceutical products | $50,075 | $48,901 | $1,174 | 2% |
| API | 3,778 | 102 | 3,676 | 3,604% |
| Total net revenues | $53,853 | $49,003 | $4,850 | 10% |
| Cost of revenues |  |  |  |  |
| Finished pharmaceutical products | $37,441 | $33,939 | $3,502 | 10% |
| API | 3,094 | 68 | 3,026 | 4,450% |
| Total cost of revenues | $40,535 | $34,007 | $6,528 | 19% |
| Gross profit | $13,318 | $14,996 | $(1,678) | (11%) |
| as % of net revenues | 25% | 31% |  |  |

Net revenues were $53.9 million and $49.0 million for the three months ended June 30, 2015 and 2014, respectively, representing an increase of $4.9 million, or 10%. The increase was largely due to the increase in sales of naloxone to $10.7 million from $4.7 million as a result of increased unit volumes at higher average prices. Additionally, we had an increase of $3.7 million in sales of recombinant human insulin and porcine insulin from our insulin business, which we acquired from Merck in April 2014, as well as, an increase of $8.9 million in sales of our other finished pharmaceutical products. These increases were partially offset by lower sales of enoxaparin, which decreased $7.7 million to $19.5 million on higher unit volumes at lower average selling prices.

We expect that the declines in the average selling price of enoxaparin will continue and that unit volume will decline in 2015 as an additional competitor, Teva, launched a competing enoxaparin product in February 2015. We believe this trend will be partially offset by pricing increases on several other finished pharmaceutical products. Net revenues would also be impacted if sales of our products were affected by any manufacturing or production issues, supply chain interruptions or unexpected regulatory issues.

Although quarterly sales may fluctuate, we anticipate that sales of insulin API will increase due to sales under our supply agreement with MannKind. Most of our API sales are denominated in Euros, and the decline in the value of the Euro versus the dollar compared to 2014 has had and will continue to have a negative impact on API sales revenues in 2015.

### Cost of revenues

Cost of revenues was $40.5 million and $34.0 million for the three months ended June 30, 2015 and 2014, respectively, representing an increase of $6.5 million, or 19%. The increase was primarily due to the overall cost of revenue at AFP of $3.1 million, relating to the cost of sales of our insulin products, as well as, costs related to an increase in unit volume of our finished pharmaceutical products. The cost of revenues as a percentage of revenues increased to 75% from 69%. This increase as a percentage of revenues was primarily due to lower pricing on enoxaparin.

The declining prices and unit volume of enoxaparin will put additional downward pressure on gross margins, but we believe this trend will be partially offset by increases in prices of several other finished pharmaceutical products.

### Selling, distribution and marketing, general and administrative, and impairment of long-lived assets

*(in thousands)*

|  | Three Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Selling, distribution, and marketing | $1,470 | $1,352 | $118 | 9% |
| General and administrative | 11,308 | 8,638 | 2,670 | 31% |
| Impairment of long-lived assets | 74 | 184 | (110) | (60%) |

General and administrative expenses were $11.3 million and $8.6 million for the three months ended June 30, 2015 and 2014, respectively, representing an increase of $2.7 million, or 31%. The increase was primarily due to an increase in corporate compensation expense, costs associated with our compliance with Sarbanes-Oxley section 404, as well as, the inclusion of expenses generated at our French subsidiary, AFP, which we acquired in April 2014.

General and administrative expenses will increase on an annual basis due to the costs associated with compliance with Sarbanes-Oxley section 404, and the full year impact of corporate public company expenses.

### Research and development

*(in thousands)*

|  | Three Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $10,726 | $5,994 | $4,732 | 79% |

Research and development expenses were $10.7 million and $6.0 million for the three months ended June 30, 2015 and 2014, respectively, representing an increase of $4.7 million, or 79%. We had an increase of $1.6 million in clinical trial expense, primarily related to our naloxone nasal product candidate. Additionally, we had an increase in expense of $2.4 million in purchases of materials and other research and development supplies, which related to the approval of Amphadase® and the development of naloxone nasal product candidate.

Research and development costs consist primarily of costs associated with the research and development of our product candidates, such as salaries and other personnel-related expenses for employees involved with research and development activities, manufacturing pre-launch inventory, clinical trials, FDA fees, testing, operating and lab supplies, depreciation and amortization and other related expenses. We expense research and development costs as incurred.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. These costs will fluctuate significantly from quarter to quarter based on the timing of various clinical trials, the pre-launch costs associated with new products, and FDA filing fees. As we undertake new and challenging research and development projects, we anticipate that the associated annual costs will increase significantly over the next several years.

The following table sets forth our research and development expenses for the three months ended June 30, 2015 and 2014:

*(in thousands)*

|  | Three Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Salaries and personnel-related expenses | $3,472 | $2,662 | $810 | 30% |
| Pre-launch inventory | — | 331 | (331) | (100%) |
| Clinical trials | 1,772 | 197 | 1,575 | 799% |
| FDA fees | 59 | — | 59 | N/A |
| Testing, operating and lab supplies | 3,612 | 1,211 | 2,401 | 198% |
| Depreciation and amortization | 993 | 922 | 71 | 8% |
| Other expenses | 818 | 671 | 147 | 22% |
| Total research and development expenses | $10,726 | $5,994 | $4,732 | 79% |

- *31-*

### Provision for income tax benefit

*(in thousands)*

|  | Three Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Income tax benefit | $3,582 | $696 | $2,886 | 415% |
| Effective tax rate | 35% | 37% |  |  |

Income tax benefit was $3.6 million and $0.7 million for the three months ended June 30, 2015 and 2014, respectively, representing an increase in income tax benefit of $2.9 million, or 415%. The increase in income tax benefit was primarily related to the pre-tax loss that occurred during the three months ended June 30, 2015.

### Six Months Ended June 30, 2015 Compared to Six Months Ended June 30, 2014

### Net revenues

*(in thousands)*

| Net revenues Finished pharmaceutical products | Six Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Enoxaparin | $43,383 | $53,297 | $(9,914) | (19%) |
| Other products | 57,564 | 41,474 | 16,090 | 39% |
| Total finished pharmaceutical products | $100,947 | $94,771 | $6,176 | 7% |
| API | 9,792 | 102 | 9,690 | 9,500% |
| Total net revenues | $110,739 | $94,873 | $15,866 | 17% |
| Cost of revenues |  |  |  |  |
| Finished pharmaceutical products | $75,460 | $67,300 | $8,160 | 12% |
| API | 8,681 | 68 | 8,613 | 12,666% |
| Total cost of revenues | $84,141 | $67,368 | $16,773 | 25% |
| Gross profit | $26,598 | $27,505 | $(907) | (3%) |
| as % of net revenues | 24% | 29% |  |  |

Net revenues were $110.7 million and $94.9 million for the six months ended June 30, 2015 and 2014, respectively, representing an increase of $15.8 million, or 17%. The increase was largely due to the increase in sales of naloxone to $17.4 million from $8.0 million as a result of increased unit volumes at higher average prices. Additionally, we had an increase of $9.7 million in sales of recombinant human insulin and porcine insulin from our insulin business, which we acquired from Merck in April 2014, as well as, an increase of $16.1 million in sales of our other finished pharmaceutical products. These increases were partially offset by lower sales of enoxaparin, which decreased $9.9 million to $43.4 million on higher unit volumes at lower average selling prices.

We expect that the declines in the average selling price of enoxaparin will continue and that unit volume will decline in 2015 as an additional competitor, Teva, launched a competing enoxaparin product in February 2015. We believe this trend will be partially offset by pricing increases on several other finished pharmaceutical products. Net revenues would also be impacted if sales of our products were affected by any manufacturing or production issues, supply chain interruptions or unexpected regulatory issues.

Although quarterly sales may fluctuate, we anticipate that sales of insulin API will increase due to sales under our supply agreement with MannKind. Most of our API sales are denominated in Euros, and the decline in the value of the Euro versus the dollar compared to 2014 has had and will continue to have a negative impact on API sales revenues in 2015.

### Cost of revenues

Cost of revenues was $84.1 million and $67.4 million for the six months ended June 30, 2015 and 2014, respectively, representing an increase of $16.7 million, or 25%. The increase was primarily due to the overall cost of revenue at AFP of $8.6 million, relating to the cost of sales of our insulin products, as well as, costs related to an increase in unit volume of our finished pharmaceutical products. The cost of revenues as a percentage of revenues increased to 76% from 71%. This increase as a percentage of revenues was primarily due to lower pricing on enoxaparin.

The declining prices and unit volume of enoxaparin will put additional downward pressure on gross margins, but we believe this trend will be partially offset by increases in prices of several other finished pharmaceutical products.

### Selling, distribution and marketing, general and administrative, and impairment of long-lived assets

*(in thousands)*

|  | Six Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Selling, distribution, and marketing | $2,992 | $2,612 | $380 | 15% |
| General and administrative | 23,759 | 15,484 | 8,275 | 53% |
| Impairment of long-lived assets | 74 | 348 | (274) | (79%) |

General and administrative expenses were $23.8 million and $15.5 million for the six months ended June 30, 2015 and 2014, respectively, representing an increase of $8.3 million, or 53%. The increase was primarily due to an accrual of $3.2 million, plus applicable payroll taxes relating to a settlement of our California employment litigation. We had an increase of $1.2 million, relating to the cost associated with our compliance with Sarbanes-Oxley section 404, as well as, the inclusion of expenses generated at our French subsidiary, AFP, which we acquired in April 2014.

General and administrative expenses will increase on an annual basis due to the costs associated with compliance with Sarbanes-Oxley section 404, and the full year impact of corporate public company expenses.

### Research and development

*(in thousands)*

|  | Six Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $17,294 | $12,203 | $5,091 | 42% |

Research and development expenses were $17.3 million and $12.2 million for the six months ended June 30, 2015 and 2014, respectively, representing an increase of $5.1 million, or 42%. We had an increase of $1.9 million in clinical trial expense, primarily related to our naloxone nasal product candidate. Additionally, we had an increase in expense of $3.1 million in purchases of materials and other research and development supplies, which related to the approval of Amphadase® and the development of naloxone nasal product candidate.

Research and development costs consist primarily of costs associated with the research and development of our product candidates, such as salaries and other personnel-related expenses for employees involved with research and development activities, manufacturing pre-launch inventory, clinical trials, FDA fees, testing, operating and lab supplies, depreciation and amortization and other related expenses. We expense research and development costs as incurred.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. These costs will fluctuate significantly from quarter to quarter based on the timing of various clinical trials, the pre-launch costs associated with new products, and FDA filing fees. As we undertake new and challenging research and development projects, we anticipate that the associated annual costs will increase significantly over the next several years.

The following table sets forth our research and development expenses for the six months ended June 30, 2015 and 2014:

*(in thousands)*

|  | Six Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Salaries and personnel-related expenses | $6,687 | $5,587 | $1,100 | 20% |
| Pre-launch inventory | — | 1,014 | (1,014) | (100%) |
| Clinical trials | 1,870 | — | 1,870 | N/A |
| FDA fees | 174 | — | 174 | N/A |
| Testing, operating and lab supplies | 5,168 | 2,182 | 2,986 | 137% |
| Depreciation and amortization | 2,001 | 1,803 | 198 | 11% |
| Other expenses | 1,394 | 1,617 | (223) | (14%) |
| Total research and development expenses | $17,294 | $12,203 | $5,091 | 42% |

### Provision for income tax benefit

*(in thousands)*

|  | Six Months Ended June 30, 2015 | 2014 | Change Dollars% |  |
| --- | ---: | ---: | ---: | ---: |
| Income tax benefit | $9,114 | $1,548 | $7,566 | 489% |
| Effective tax rate | 55% | 36% |  |  |

Income tax benefit was $9.1 million and $1.5 million for the six months ended June 30, 2015 and 2014, respectively, representing an increase in income tax benefit of $7.6 million, or 489%. The increase in income tax benefit was primarily related to the pre-tax loss that occurred during the six months ended June 30, 2015 and the reversal of a deferred tax valuation allowance during the first quarter of 2015, which had previously been reserved.

### Liquidity and Capital Resources

### Cash Requirements and Sources

We need capital resources to maintain and expand our business. Our future capital expenditures will include projects undertaken to upgrade, expand and improve its manufacturing facilities in the United States, China and France. Our cash obligations include the principal and interest payments due on its existing loans, as described below and throughout this Quarterly Report. We believe that our cash reserves, operating cash flows, and availability under our revolving credit facility will be sufficient to fund our operations for the next 12 months. If we require or elect to seek additional capital through debt or equity financing in the future, we may not be able to raise capital on terms acceptable to us or at all. If we are required and unable to raise additional capital when desired, our business, operating results and financial condition may be adversely affected.

Working capital decreased $0.9 million to $134.5 million at June 30, 2015 compared to $135.4 million at December 31, 2014. The decrease in working capital was primarily due to payments on long-term debt of $2.5 million and capital expenditures of $7.6 million, which was partially offset by cash in-flows from operations of $3.8 million and cash provided by option exercises of $10.7 million.

### Cash Flows from Operations

The following table summarizes our cash flows used in operating, investing, and financing activities for the six months ended June 30, 2015:

*(in thousands)*

| Statement of Cash Flow Data: Net cash provided by (used in) | Six Months Ended June 30, 2015 |
| --- | ---: |
| Operating activities | $3,841 |
| Investing activities | (8,764) |
| Financing activities | 11,529 |
| Effect of exchange rate changes on cash | 29 |
| Net increase in cash and cash equivalents | $6,635 |

#### Sources and Use of Cash

#### Operating Activities

Net cash provided by operating activities was $3.8 million for the six months ended June 30, 2015, which included a net loss of $7.3 million. Non-cash items are comprised of $6.6 million of depreciation and amortization and, $5.9 million of share-based compensation expense. This was partially offset by an increase of $2.3 million in operating assets and liabilities and a $3.9 million change in deferred taxes and other tax related items

#### Investing Activities

Net cash used in investing activities of $8.8 million for the six months ended June 30, 2015 was primarily related to $7.6 million in purchases of property, machinery, and equipment, including the associated capitalized labor and interest on self-constructed assets. Additionally, $1.4 million in deposits were made for machinery and equipment.

*Financing Activitie*s

Net cash provided by financing activities of $11.5 million for the six months ended June 30, 2015 was primarily related to $6.8 million in additional borrowings and $10.7 million from proceeds of stock options exercised. This was partially offset by $3.5 million relating to the repurchase of our common stock and $2.5 million in principal payments on our long-term debt.

### Contractual Obligations

There have been no material changes outside the ordinary course of our business in the contractual obligations disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014, except that our outstanding debt obligations have changed as follows:

*(in thousands)*

|  | June 30, 2015 | December 31, 2014 | Change |
| --- | ---: | ---: | ---: |
| Short-term debt and current portion of long-term debt | $12,632 | $7,594 | $5,038 |
| Long-term debt | 34,798 | 36,106 | (1,308) |
| Total debt | $47,430 | $43,700 | $3,730 |

The increase in outstanding debt is primarily related to the debt associated with the $6.2 million draw down from our line of credit in January 2015, which was subsequently converted into an equipment loan that matures in January 2019.

As of June 30, 2015, we had $30.0 million in unused borrowing capacity under revolving lines of credit with Cathay Bank and East West Bank.

We have entered into a collaboration agreement with a medical device manufacturer to develop a drug delivery system to be used by us for one of our pipeline products. As of June 30, 2015 we have paid an upfront payment of $0.5 million and a $0.1 million milestone payment under this agreement, which was classified as research and development expense. We are obligated to pay up to an additional $1.9 million if certain milestones are met. If the medical device manufacturer is successful in the development of this drug delivery system and the Company’s pipeline products receives appropriate regulatory approval, we intend to enter into a commercial supply agreement with such medical device manufacturer for a minimum purchase of 1.0 million units during the first 12 months.

### Recent Accounting Pronouncements

In April 2014, the FASB issued an accounting standards update that raised the threshold for disposals to qualify as discontinued operations and allows companies to have significant continuing involvement with and continuing cash flows from or to the discontinued operation. It also requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. This guidance is effective for fiscal years beginning after December 15, 2014, which is our fiscal year 2015, with early adoption permitted. The adoption of the guidance did not have a material impact on our consolidated financial statements.

In May 2014, the FASB issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2017, which will be our fiscal year 2018. We have not yet evaluated the potential impact of adopting the guidance on our consolidated financial statements.

In June 2014, the FASB issued an accounting standards update that requires a performance target that affects vesting of a share-based payment award and that could be achieved after the requisite service period to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized over the required service period, if it is probable that the performance target will be achieved. This guidance will be effective for fiscal years beginning after December 15, 2015, which will be our fiscal year 2016, with early adoption permitted. We do not expect the adoption of the guidance will have a material impact on our consolidated financial statements.

In August 2014, the FASB issued an accounting standards update that will require management to evaluate if there is substantial doubt about the Company’s ability to continue as a going concern and, if so, to disclose this in both interim and annual reporting periods. This guidance will become effective for our annual filing for the period ending December 31, 2016 and interim periods thereafter, and allows for early adoption. We do not expect the adoption of the guidance will have a material impact on our consolidated financial statements.

In July 2015, the FASB issued an accounting standards update which requires entities to measure most inventory at the lower of cost and net realizable value, or NRV, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is measured at the lower of cost and net realizable value, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods therein. The standard will be effective for us for the first quarter of our fiscal year 2016. Early application is permitted. The new guidance must be applied prospectively. We do not believe the adoption of this accounting guidance will have a material impact on our consolidated financial statements and related disclosures.

### Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

### Government Regulation

Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The Food and Drug Administration, or FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products. The Drug Enforcement Administration, or DEA, maintains oversight over our products that are considered controlled substances.

From January 19 through 22, 2015, our facility in Éragny-Sur-Epte, France was subject to an inspection by the French National Agency for Medicines and Health Products Safety (Agence nationale de sécurité du médicament et des produits de santé), or ANSM. The inspection included a review of current EU Good Manufacturing Practices for Medicinal Products for Human and Veterinary Use (EU-GMP Part II for Active Substances) and Manufacture of Biological Active Substances and Medicinal Products for Human Use (EU-GMP Annex 2). The inspections resulted in various observations issued formally to the facility. We responded to those observations on March 13, 2015, with a minor follow up response on April 3, 2015. We received acknowledgment from ANSM that our responses to the observations were satisfactorily addressed and was issued a certificate of GMP compliance from the Agency dated April 9, 2015 that is valid until January 2018.

On July 22, 2015 through August 10, 2015, our IMS facility in South El Monte, CA was subject to an inspection by the FDA. The inspection included a review of cGMP and preapproval inspections for abbreviated new drug applications currently being reviewed by the FDA. The inspections resulted in multiple observations on Form 483, an FDA form on which deficiencies are noted after an FDA inspection. We plan to respond to those observations by August 31, 2015.

## Market risk

As filed, 4,588 characters.

The following discussion provides forward-looking quantitative and qualitative information about our potential exposure to market risk. Market risk represents the potential loss arising from adverse changes in the value of financial instruments. The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk), and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).

#### Investment Risk

We regularly review the carrying value of our investments and identify and recognize losses, for income statement purposes, when events and circumstances indicate that any declines in the fair values of such investments below our accounting basis are other than temporary. As of June 30, 2015, we did not have any such investments.

As of June 30, 2015, we had $6.9 million deposited in three banks located in China and $3.9 million deposited in one bank located in France. We also maintained $47.8 million in Money Market, Money Market Insured Deposit Account Service, or MMIDAS, and Insured Cash Sweep, or ICS, accounts as of June 30, 2015. The remaining amounts of our cash equivalent as of June 30, 2015 are in non-interest bearing accounts.

The MMIDAS accounts and ICS accounts allow us to distribute our funds among a network of depository institutions that are re-allocated such that each deposit account is below the $250 thousand Federal Deposit Insurance Corporation, or FDIC, limit, thus providing greater FDIC insurance coverage for our overall cash balances. We have not experienced any losses in such accounts, nor does management believe we are exposed to any significant credit risk on our bank account balances.

#### Interest Rate Risk

Our primary exposure to market risk is interest-rate-sensitive investments and credit facilities, which are affected by changes in the general level of U.S. interest rates. Due to the nature of our short-term investments, such as our certificates of deposit, we believe that we are not subject to any material interest rate risk with respect to our short-term investments.

As of June 30, 2015, we had $47.4 million in long-term debt and capital leases outstanding. Of this amount, $33.8 million had variable interest rates with a weighted-average interest rate of 4.1% at June 30, 2015. An increase in the index underlying these rates of 1% (100 basis points) would increase our annual interest expense on the variable-rate debt by approximately $0.3 million per year.

#### Foreign Currency Rate Risk

Our products are primarily sold in U.S. domestic market, and for the three and six months ended June 30, 2015 and 2014, foreign sales were minimal. Therefore, we had little exposure to foreign currency price fluctuations. However, as a result of our acquisition of API manufacturing business in Éragny-sur-Epte, France, we are exposed to market risk related to changes in foreign currency exchange rates. Specifically, our insulin sales contracts are primarily denominated in Euros, which are subject to fluctuations relative to the U.S. dollar, or USD. We do not currently hedge our foreign currency exchange rate risk. At this time, an immediate 10% change in currency exchange rates could have a material effect on our financial position, results of operations or cash flows.

Our Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Limited, or ANP, maintains its books of record in Chinese Yuan, or CNY. These books are remeasured into the functional currency of USD, using the current or historical exchange rates. The resulting currency re-measurement adjustments and other transactional foreign exchange gains and losses are reflected in our statement of operations.

Our French subsidiary, Amphastar France Pharmaceuticals, S.A.S., or AFP, maintains its books of record in Euros. These books are translated to USD at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive loss. We do not undertake hedging transactions to cover its foreign currency exposure.

As of June 30, 2015, our foreign subsidiaries had receivables denominated in foreign currencies in the amount of $3.0 million.

## Controls and procedures

As filed, 3,752 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective to provide reasonable assurance that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Internal control over financial reporting means a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

### Inherent Limitations of Internal Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## Risk factors

As filed, 214 characters.

There were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 26, 2015.

Filed Aug 13, 2015.
Source: SEC EDGAR, the filing index for accession 0001171843-15-004674. Last ingested by Listed: Nov 6, 2026, 17:01 ET. No prices; not investment advice.
